1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Numerous Independent Groups Presented Data that Supports Apabetalone’s Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
September 3, 2024
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
July 31, 2024
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
May 28, 2024
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
May 13, 2024
Resverlogix Announces Change to its Board of Directors
February 21, 2024
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone’s Potential Therapeutic Benefits
January 11, 2024